|1.||Qureshi, Adnan I: 11 articles (08/2014 - 11/2002)|
|2.||Topol, Eric J: 6 articles (02/2010 - 11/2002)|
|3.||Svensson, Leif: 5 articles (12/2010 - 04/2003)|
|4.||Herlitz, Johan: 5 articles (12/2010 - 04/2003)|
|5.||Kirmani, Jawad F: 5 articles (01/2007 - 12/2002)|
|6.||Suri, M Fareed K: 5 articles (01/2007 - 11/2002)|
|7.||Betriu, Amadeo: 4 articles (02/2010 - 11/2002)|
|8.||Barnathan, Elliot S: 4 articles (02/2010 - 02/2004)|
|9.||Savonitto, Stefano: 4 articles (10/2009 - 11/2002)|
|10.||Lincoff, A Michael: 4 articles (10/2007 - 07/2002)|
07/01/2008 - "Intraarterial thrombolysis with reteplase in acute ischaemic stroke in a Pakistani center."
02/01/2004 - "Patients treated for acute ischemic stroke at our center between September 2000 and May 2002 received a maximum total dose of 4 U of reteplase intra-arterially in 1-U increments via superselective catheterization. "
01/01/2013 - "Reteplase is a potent thrombolytic agent which is widely used in the management of acute myocardial infarction and stroke. "
05/01/2008 - "The beneficial effect of subthrombolytic doses of reteplase on microvascular hemodynamics distal to a cortical arteriolar thrombosis is markedly enhanced by the coadministration of high-dose albumin therapy; these results have important clinical implications for the management of patients with acute ischemic stroke."
01/01/2007 - "The 35-day mortality rates were equivalent for reteplase and streptokinase recipients; there was reduced incidence of some cardiac events with reteplase versus streptokinase, but a greater incidence of hemorrhagic stroke. "
04/01/2015 - "To assess the safety and efficacy of intravenous Retelex (Reteplase) injection in management of patients with ST elevated myocardial infarction in clinical practice. "
10/01/2015 - "This study was aimed to examine the reteplase pattern of ADR and its associated risk factors in patients with acute ST-elevation myocardial infarction. "
04/01/2015 - "Reteplase is commonly used in the management of ST elevated myocardial infarction. "
05/01/2013 - "A total of 224 patients with acute ST-segment elevation myocardial infarction who received thrombolysis with reteplase were randomly assigned to an early percutaneous coronary intervention (E-PCI) group or a selective PCI (S-PCI) group. "
01/01/2010 - "Reteplase (rPA) is a thrombolytic agent used for the treatment of acute myocardial infarction. "
|3.||Arterial Occlusive Diseases (Arterial Occlusive Disease)
03/01/2004 - "The safety and efficacy of increasing doses of intraarterial reteplase monotherapy and reteplase/abciximab combination therapy were examined in patients with acute peripheral arterial occlusive disease (PAOD). "
03/01/2004 - "Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial."
01/01/2002 - "Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study."
03/01/2000 - "Reteplase shows promise as an alternative to urokinase in the treatment of lower extremity ischemia due to arterial occlusive disease."
02/01/2004 - "Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion."
11/01/2003 - "The authors prospectively evaluated the safety and efficacy of reteplase in restoring patency to occluded CVCs in children with cancer. "
01/01/2004 - "Reteplase at 0.4-U dosing per catheter lumen is an effective and safe alternative that rapidly restores the patency of occluded CVCs in patients with cancer."
01/01/2004 - "Reteplase (0.4 U) was instilled into each catheter lumen with a dwell time of 30 minutes in patients with cancer with a dysfunctional CVC. "
01/01/2004 - "To evaluate the efficacy and safety of reteplase for central venous catheter (CVC) occlusion in patients with cancer. "
01/01/2004 - "Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer."
10/01/2007 - "Reteplase may prove safe and effective as a provocative agent, stimulating bleeding to allow localization, in patients with occult, recurrent, massive LGIB."
12/01/1996 - "All three studies demonstrated that reteplase therapy was not associated with an increase in bleeding complications or other adverse clinical events. "
10/01/1996 - "As with other thrombolytics, bleeding was the most common adverse event seen in reteplase recipients. "
01/01/2006 - "Across studies in these indications, the incidence of bleeding complications associated with reteplase treatment appeared to be similar to that associated with other thrombolytic agents. "
06/01/2006 - "Patients who received reteplase plus abciximab tended to develop more minor complications (mainly bleeding events) (P<.001). "
|2.||Tissue Plasminogen Activator (Alteplase)
|5.||glucuronyl glucosamine glycan sulfate (Vessel)
|6.||Plasminogen Activators (Plasminogen Activator)
|7.||Platelet Membrane Glycoprotein IIb
|8.||Fibrinolytic Agents (Antithrombotic Agents)
|2.||Angioplasty (Angioplasty, Transluminal)